Considering the known diverse (opposite on some occasions) and contextual roles of CCN3 in different physiological and pathophysiological conditions, our studies do not imply a potential for exploiting the use of CCN3 for therapy, rather, our observations highlight the novel role of myeloid CCN3 in mitigating CAVD progression. This evidence concerns the gene CCN3 and congenital bilateral aplasia of vas deferens from CFTR mutation.